Sarepta Therapeutics Cash Flow - Annual (NASDAQ:SRPT)

Add to My Stocks
$36.13 $1.7 (4.49%) SRPT stock closing price Jan 17, 2017 (Closing)

The Sarepta Therapeutics cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. Financials statements like the income statement and balance sheet show that the company has Sarepta Therapeutics profits and Sarepta Therapeutics debt, while the cash flow statement provides details of cash flow movments. The cash flow statement is essetial while conducting the Sarepta Therapeutics cash flow analysis and can be used to measure the operating performance of Sarepta Therapeutics compared to various industry peers like LGND stock and JUNO stock. Sarepta Therapeutics has a positive cash and cash equivalents change of $6.75M. View details of Sarepta Therapeutics cash flows for latest & last ten financial years.

show more
Annual
Quarterly
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
Sarepta Therapeutics Net Income Cash Flow
-220.03M-135.78M-111.98M-121.28M-2.31M-32.17M-25.15M-23.95M-27.16M-31.07M
Depreciation Depletion Amortization Cash-Flow5.89M6.12M1.27M1.52M1.3M1.46M1.37M1.46M2.01M2.09M
Net Increase (Decrease) in Assets Liabilities31.98M-22.13M12.26M-5.3M6.93M-0.35M2.93M-2.82M-0.35M1.39M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net32.68M23.26M33.74M95.37M-29.59M15.85M12.04M12.96M0.83M6.97M
Sarepta Therapeutics Net Cash from (used by) Operating Activities
-149.46M-128.53M-64.69M-29.69M-23.67M-15.2M-8.8M-12.33M-24.67M-20.61M
Increase (Decrease) in Prop Plant And Equipment-3.4M-25.44M-2.37M-0.1M-1.17M-0.83M-0.93M-0.36M-1.27M-0.76M
Acquisition Disposition of Subsidiaires--------0.01M--
Increase (Decrease) in Investments13.24M-132.2M-7.89M---0.01M0.11M-0.01M12.7M-0.53M
Other Cash Inflow (Outflow) from Investment Activities-1.43M-1.38M-1.4M-1.03M-1.12M-1.12M-1.06M-0.84M-0.85M-0.68M
Sarepta Therapeutics Net Cash from (used by) Invesment Activities
8.41M-159.03M-11.67M-1.14M-2.3M-1.96M-1.88M-1.23M10.57M-1.98M
Issuance (Purchase) of Equity Shares130.8M104.24M145.98M178.68M32.38M2.56M47.84M0.08M18.74M8.16M
Issuance (Repayment) of Debt Securities17M-0.09M-0.08M-0.08M-0.08M-0.07M-0.07M-0.11M--
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities
Sarepta Therapeutics Net Cash from (used by) Financing Activities
147.8M104.15M145.67M178.59M32.29M2.48M47.76M-0.03M18.74M8.16M
Effect of Exchange Rate Changes on Cash----------
Sarepta Therapeutics Net Change in Cash & Cash Equivalents
6.75M-183.41M69.3M147.75M6.31M-14.68M37.08M-13.61M4.64M-14.43M
Cash & Equivalents at Beginning of Year73.55M256.96M187.66M39.9M33.58M48.27M11.19M24.8M20.15M34.59M
Cash & Equivalents at Year End80.3M73.55M256.96M187.66M39.9M33.58M48.27M11.19M24.8M20.15M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Cash flow for another ticker

1:11
SRPT
Sarepta Therapeutics stock comparison chart provides an easy way to compare the stock price with peers along with details of Sarepta Therapeutics stock price history.
The statement of cash flows can be categorized into three main sections:
  • Sarepta Therapeutics has cash of $80.3M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Sarepta Therapeutics stock price.
  • Sarepta Therapeutics decreased its cash from operating activities to $20.93M in 2015. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash from investing stood at a positive value of $8.41M for SRPT stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $147.8M for Sarepta Therapeutics.
.